Announcement • Jun 22
Atlas Energy Corp. Announces Appointments to Subsidiary Board Atlas Energy Corp. announced that Patrick Drouin and Dion Degrand will be appointed to the board of directors of Atlas Energy International SEZC, the Company’s Cayman Islands subsidiary, subject to receipt of applicable Cayman Islands regulatory approvals. Patrick Drouin is the President of Wheaton Precious Metals International and Chief Sustainability Officer for the Wheaton group. Before being appointed President in October 2023, Mr. Drouin was the Senior Vice President of Sustainability & Investor Relations at Wheaton Precious Metals, an executive role primarily responsible for the company’s sustainability efforts and engaging with the investment community. Prior to Wheaton, Mr. Drouin worked for UBS Securities from 2001 to 2012 in institutional equity sales across North America and Europe, most recently in London as Head of European Sales for UBS Canada. In this role, Mr. Drouin built a sales platform responsible for advising fund managers on Canadian equities. Throughout his advisory career, he has focused on the resource sector. Prior to UBS, he served as a Project Geologist in the San Francisco Bay Area for William Lettis & Associates. Mr. Drouin has an MBA from the Rotman School of Management, University of Toronto, and a Masters in Geology from the University of Memphis. Dion Degrand is the Chief Executive Officer of the Rawlinson & Hunter group of companies in the Cayman Islands, providing a full range of professional services including fiduciary, trust and corporate, fund governance and administration, accounting, restructuring and compliance services to international clients. Mr. Degrand has over 30 years of experience across investment banking, public and private capital markets, accounting, international banking, and independent governance. Prior to relocating to the Cayman Islands, Mr. Degrand spent the majority of his career in oil and gas investment banking, holding senior positions at leading investment banks, including Head of Canadian Energy at Raymond James (Canada), Head of Energy and Head of Western Canada at Cormark Securities, Managing Director at National Bank Financial and Principal at Peters & Co. Limited. Mr. Degrand is a CA, CPA and CFA charterholder, and a CIMA-registered director under the Cayman Islands Directors Registration and Licensing Act. Board Change • May 20
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Gary Brown is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • May 07
Willow Biosciences Inc. announced that it expects to receive CAD 30 million in funding Willow Biosciences Inc. announced a private placement of 3,000,000,000 common shares and units at a price of CAD 0.01 for the gross proceeds of CAD 30,000,000 on May 7, 2025. Each unit will consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.01 per share. The Company may pay fees to certain advisory firms that assist in the placement of the Private Placement. Units will be issued to subscribers that are members of the New Executive Team and the New Board, together with certain additional subscribers identified by such persons. Common Shares will be issued to all other subscribers. The New Executive Team will be led by Mark Hodgson as President and Chief Executive Officer, Travis Doupe as Chief Financial Officer, Don Kornelsen as Vice President, Commercial, Ryan Giroux as Vice President, Corporate Development and Blair Anderson as Vice President, Geoscience of the Company and Richard Naden as a Senior Executive. The New Board will be comprised of Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price. Announcement • May 01
Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million. Mycofeast Ltd entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Willow Biosciences Inc. must pay $0.5 million to Mycofeast Ltd if it terminates the deal. The deal is expected to be closed before April 30, 2025.
Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million on April 30, 2025. Announcement • Mar 27
Willow Biosciences Inc. Auditor Raises 'Going Concern' Doubt Willow Biosciences Inc. filed its Annual on Mar 25, 2025 for the period ending Dec 31, 2024. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Announcement • Mar 19
Willow Biosciences Inc., Annual General Meeting, Apr 25, 2025 Willow Biosciences Inc., Annual General Meeting, Apr 25, 2025. Announcement • Mar 16
An undisclosed buyer entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million. An undisclosed buyer entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Announcement • Nov 18
Willow Biosciences Inc. announced that it expects to receive CAD 2.001341 million in funding Willow Biosciences Inc. announced a non-brokered private placement on a best efforts basis of a minimum of 10,000,000 units at a price of CAD 0.08 per unit for minimum gross proceeds of CAD 800,000; and a maximum of up to 25,016,762 units at a price of CAD 0.08 per unit for maximum gross proceeds of CAD 2,001,340.96 on November 18, 2024.Each unit shall consist of one common share and one-half of one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at an exercise price of CAD 0.11 per common share for a period of 36 months from the closing of the offering. The closing will take place on such date or dates as may be determined by the company, and, in any event, on or before January 2, 2025. The closing of the offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. The company may pay a finder's fee in connection with the offering to eligible arm's length finders in accordance with the policies of the TSX. Reported Earnings • Nov 14
Third quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023) Third quarter 2024 results: CA$0.01 loss per share (improved from CA$0.018 loss in 3Q 2023). Revenue: CA$1.70m (up 153% from 3Q 2023). Net loss: CA$1.25m (loss narrowed 44% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings. New Risk • Sep 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.58m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$55k). Market cap is less than US$10m (€8.58m market cap, or US$9.58m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (CA$1.8m revenue, or US$1.4m). New Risk • Aug 13
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$55k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CA$55k). Market cap is less than US$10m (€8.65m market cap, or US$9.45m). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (CA$1.8m revenue, or US$1.3m). Reported Earnings • Aug 13
Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2023) Second quarter 2024 results: CA$0.01 loss per share (improved from CA$0.029 loss in 2Q 2023). Revenue: CA$1.03m (up CA$891.0k from 2Q 2023). Net loss: CA$1.69m (loss narrowed 53% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Announcement • Aug 13
Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024 Willow Biosciences Inc. provided earnings guidance for the fiscal year 2024. The Company remains steadfast in its revenue expectations for Fiscal Year 2024 revenues To be in excess of $4 million, an increase of almost 350% over 2023. This revenue expectation for Fiscal year 2024 is forecast to be driven from existing programs. In addition to the new programs that have already been announced so far in 2024, the Company expects to add at least one more fully funded, partnered program as well as one new internal program before the end of 2024. Announcement • Jul 18
Willow Biosciences Inc. announced that it has received CAD 1.639737 million in funding On July 18, 2024, Willow Biosciences Inc closed the transaction. The company issued 16,397,365 units at an issue price of CAD 0.10 per Unit to raise aggregate gross proceeds of up to CAD 1,639,736.50. The Agent received a cash commission of $86,992.10 and was issued 869,921 non-transferable broker warrants. Each Broker Warrant will entitle the Agent to purchase one (1) Unit for a period of 36 months following Closing, with 824,921 Broker Warrants being exercisable at the Issue Price, and 45,000 Broker Warrants being exercisable at the Exercise Price. The Offering remains subject to the final approval of the TSX. Announcement • Jun 08
Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024 Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024. Announcement • Jun 05
Willow Biosciences Inc. announced that it expects to receive CAD 3 million in funding Willow Biosciences Inc. announced a private placement of 30,000,000 units at an issue price of CAD 0.10 per Unit to raise aggregate gross proceeds of up to CAD 3,000,000 on June 3, 2024. Each Unit issued under the Offering shall consist of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of CAD 0.13 per Common Share for a period of 36 months from the closing of the Offering. The Closing will take place on such date or dates as may be agreed upon by the Company and the Agent, and, in any event, on or before July 18, 2024, being the date that is 45 days from the date hereof. Closing of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. The Company has also granted the Agent an option, exercisable in whole or in part, to sell such number of additional Units, as is equal to 15% of the number of Units of the Company issued pursuant to the Offering. The Over-Allotment Option may be exercised by the Agent for a period of 30 days from and including the Closing. Reported Earnings • May 14
First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 1Q 2023) First quarter 2024 results: CA$0.02 loss per share (improved from CA$0.039 loss in 1Q 2023). Revenue: CA$51.0k (down 81% from 1Q 2023). Net loss: CA$2.36m (loss narrowed 51% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 31
Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.12 loss in FY 2022) Full year 2023 results: CA$0.10 loss per share (improved from CA$0.12 loss in FY 2022). Revenue: CA$1.17m (up 43% from FY 2022). Net loss: CA$13.0m (loss narrowed 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. New Risk • Mar 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Revenue is less than US$5m (CA$1.6m revenue, or US$1.2m). Market cap is less than US$100m (€9.94m market cap, or US$10.8m). Announcement • Feb 21
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc. Willow Biosciences Inc. announced a non-brokered equity private placement to issue units at a issue price of CAD 0.10 per Unit to new investor, Kalsec Inc on February 20, 2024. Each Unit consisting of one common share and one-half of one Common Share purchase warrant. Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.14 per Common Share until February 20, 2025; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Common Shares on the Toronto Stock Exchange or other principal exchange on which the Common Shares are listed, is greater than CAD 0.18, the company may accelerate the expiry date of the warrants to the date that is 20 days following the date of the notice of such acceleration. Subject to the completion of an operational milestone by Willow to develop a strain that meets certain performance criteria, Kalsec agreed to subscribe for and purchase an additional CAD 135,141($100,000) of Units at a price per Unit equal to the greater of CAD 0.10; and a discount of 10% to the volume weighted average trading price of Common Shares on the TSX for the five business days ended on the completion date of the Milestone. All securities issued under the Financing, including securities issuable on exercise thereof, are subject to a hold period in Canada of four months and one day in accordance with applicable securities legislation.
On same date, the company issued 1,359,856 units at a subscription price of CAD 0.10 per Unit for gross proceeds CAD 135,985.6 in its first tranche. Reported Earnings • Nov 15
Third quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.032 loss in 3Q 2022) Third quarter 2023 results: CA$0.02 loss per share (improved from CA$0.032 loss in 3Q 2022). Revenue: CA$674.0k (up CA$625.0k from 3Q 2022). Net loss: CA$2.23m (loss narrowed 44% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Announcement • Oct 26
Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences Inc Aurora Cannabis Inc. announced the company and WILLOW BIOSCIENCES, INC. (Willow) have successfully completed a confidential settlement resolving the ongoing patent litigation between the two parties in Canada. Aurora commenced a patent infringement action in July 2021, alleging that Willow's biosynthetic process for synthesizing cannabinoids infringed Aurora's exclusive rights to patents co-owned by the University of Saskatchewan and the National Research Council (NRC). The technology of the asserted patents was invented by Anandia co-founder and former Chief Science Officer at Aurora, Jonathan Page and his colleagues, following their work at the University of Saskatchewan and the NRC, identifying key enzymes and corresponding genes in the biosynthetic pathways of cannabis plants. In December 2022, Willow announced that it had consolidated its R&D operations, transferring equipment and key personnel from its Canadian facilities to Mountain View, California. Announcement • Oct 12
Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding On October 10, 2023, Willow Biosciences Inc. closed the transaction. The company has received CAD 800,000 of the convertible debenture units. The Offering was led by insiders including members of the Board of Directors and members of the senior management team of the Company, who subscribed for a total of CAD 515,000. Each Debenture Unit consists of one 12% unsecured convertible debenture in the principal amount of CAD 1,000 due October 10, 2026 and 4,762 common share purchase warrants. Each Warrant entitles the holder thereof to purchase one common share of the Company at a price of CAD 0.105 per Share until October 10, 2025; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Shares on the Toronto Stock Exchange or other principal exchange on which the Shares are listed, is greater than CAD 0.15, the Company may accelerate the expiry date of the Warrants to the date that is 20 days following the date of the notice of such acceleration. Announcement • Sep 14
Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding Willow Biosciences Inc. announce the offering of convertible debenture units for aggregate proceeds of up to CAD 1,200,000 on September 12, 2023.This offering is being led by insiders including members of the Board of Directors and members of the senior management team of the Company, who are expected to subscribe to approximately 50% of the total funds raised. The Offering is currently open only to accredited investors. Each Debenture Unit will consist of one 12% unsecured convertible debenture in the principal amount of CAD 1000 with a maturity date of 36 months after the closing of the financing and 4,762 common share purchase warrants. Each Warrant will entitle the holder thereof to purchase one common share of the Company at a price of CAD 0.105 per Share for a period of 24 months; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Shares on the Toronto Stock Exchange (the "TSX"), or other principal exchange on which the Shares are listed, is greater than CAD 0.15, the Company may accelerate the expiry date of the Warrants to the date that is 20 days following the date of the notice of such acceleration. The Convertible Debentures will be convertible at the holder's option into Shares at any time prior to the earlier of the business day immediately preceding the Maturity Date and the date fixed for redemption of the Convertible Debentures at a conversion price of CAD 0.105 per Share. Interest on the Convertible Debentures will be payable semi-annually in arrears, beginning on December 31, 2023.The offering is expected to close on or about September 29, 2023.All securities issued under the Offering, including securities issuable on conversion or exercise thereof, will be subject to a hold period in Canada of four months and one day following the Closing Date in accordance with applicable securities legislation. Announcement • Sep 07
Willow Biosciences Inc. Announces Successful Completion of R&D Program on Covid Willow Biosciences Inc. announced that it has successfully completed research and development on its program to produceursodeoxycholic acid ("UDCA"), a large volume active pharmaceutical ingredient ("API") used in nutraceutical and pharmaceutical products. UDCA has applications as a medication for management and treatment of cholestatic liver disease and gallstone conditions, and as an intermediate for production of tauroursodeoxycholic acid (TUDCA), a key API in a combination therapy recently approved in Canada and the United States for treatment of amyotrophic lateral sclerosis (ALS). Through this partnered program with Sandhill One, LLC ("Sandhill"), Willow has now optimized a proprietary enzyme vital to the development of UDCA while solving for selective C-H hydroxylation at industrial scale - often referred to as one of the "Holy Grails" of chemistry. This breakthrough was made possible by Willow's BioOxi technology, and believe marks the first example of commercially relevant productivities with this class of enzyme. This successful outcome further illustrates that the BioOxi platform is broadly applicable to the manufacturing of intermediates and APIs, particularly steroid APIs. With R&D now complete, Willow anticipates receiving milestone payments and revenue upon commercialization by Sandhill. Announcement • Aug 31
Willow Biosciences Inc. Announces Filing of Patent Application for Process to Produce Corticosteroids At Significantly Reduced Cost Willow Biosciences Inc. announced the development of a process to produce corticosteroids at significantly reduced cost by utilizing its BioOxi platform for efficient bio-hydroxylation that can transform manufacturing. Corticosteroids are broadly used as anti-inflammatory and immunosuppressant drugs. According to independent research firm, ResearchandMarkets, the global corticosteroids market is expected to grow at a CAGR of 4.1% and reach $5.93 billion in 2026 and North America was the larger region for use of corticosteroids in 2022. A large percentage of corticosteroid production is outside the United States, which can pose supply chain security issues for drug manufacturers and potentially lead to drug shortages. Willow's innovative BioOxi process represents a step change by significantly reducing production costs and is expected to be sufficiently competitive to enable greater onshoring of corticosteroid manufacturing, leading to a more secure domestic supply chain. Coupled with pending patent protection, should it be granted, Willow believes this wholly-owned technology will provide a significant competitive advantage to potential pharmaceutical manufacturing partners. By leveraging BioOxi, commercial partners can revolutionize the manufacturing process of hydroxylated functional ingredients such as steroids, polyphenols, oxyterpenes, and other ingredients. Announcement • Aug 25
Willow Biosciences Inc. Announces Board Changes Willow Biosciences Inc. announced that the company is reducing the size of its board of directors (the "Board") from nine to five members. Chairman of the Board and Founder of the Company, Mr. Trevor Peters, and Directors Ms. Barbara Munroe, Dr. Fotis Kalantzis and Dr. Peter Seufer-Wasserthal stepped down from the Board effective from August 24, 2023. The Board now consists of Dr. Chris Savile, Willow's President & CEO, Mr. Al Foreman, Mr. Raffi Asadorian, Mr. Don Archibald and Dr. Jim Lalonde. Dr. Jim Lalonde succeeds Mr. Peters as Chairman of the Board. New Risk • Aug 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.84m (US$9.70m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$16m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Revenue is less than US$1m (CA$1.1m revenue, or US$815k). Market cap is less than US$10m (€8.84m market cap, or US$9.70m). Announcement • May 13
Willow Biosciences Inc. Announces Executive Changes Willow Biosciences Inc. at the annual general and special meeting of shareholders held on May 12, 2023, Mr. Raffi Asadorian was appointed as an independent director to the board of directors of Willow to succeed Mr. Sadiq Lalani who had served on the Board since April 2019 and had decided not to stand for re-election due to other commitments. Reported Earnings • Mar 22
Full year 2022 earnings released: CA$0.12 loss per share (vs CA$0.051 loss in FY 2021) Full year 2022 results: CA$0.12 loss per share (further deteriorated from CA$0.051 loss in FY 2021). Net loss: CA$14.8m (loss widened 141% from FY 2021). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Board Change • Nov 17
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Lead Independent Director Barb Munroe was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 05
Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.031 profit in 3Q 2021) Third quarter 2022 results: CA$0.03 loss per share (down from CA$0.031 profit in 3Q 2021). Net loss: CA$3.99m (down 204% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 16
Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.053 profit in 2Q 2021) Second quarter 2022 results: CA$0.03 loss per share (down from CA$0.053 profit in 2Q 2021). Net loss: CA$3.15m (down 148% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Reported Earnings • May 15
First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.10 loss in 1Q 2021) First quarter 2022 results: CA$0.02 loss per share (up from CA$0.10 loss in 1Q 2021). Net loss: CA$2.97m (loss narrowed 74% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Barb Munroe was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 31
Full year 2021 earnings released: CA$0.05 loss per share (vs CA$0.41 loss in FY 2020) Full year 2021 results: CA$0.05 loss per share (up from CA$0.41 loss in FY 2020). Net loss: CA$6.14m (loss narrowed 82% from FY 2020). Reported Earnings • Mar 31
Full year 2021 earnings released: CA$0.05 loss per share (vs CA$0.41 loss in FY 2020) Full year 2021 results: CA$0.05 loss per share (up from CA$0.41 loss in FY 2020). Net loss: CA$6.14m (loss narrowed 82% from FY 2020). Reported Earnings • May 09
First quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.018 loss in 1Q 2020) First quarter 2021 results: Net loss: CA$11.3m (loss widened CA$9.89m from 1Q 2020). Is New 90 Day High Low • Feb 06
New 90-day high: €1.07 The company is up 182% from its price of €0.38 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 14
New 90-day high: €0.84 The company is up 93% from its price of €0.44 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 22
New 90-day high: €0.51 The company is up 5.0% from its price of €0.49 on 22 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period. Recent Insider Transactions • Nov 01
President recently bought €123k worth of stock On the 29th of October, Trevor Peters bought around 295k shares on-market at roughly €0.42 per share. This was the largest purchase by an insider in the last 3 months. Trevor has been a buyer over the last 12 months, purchasing a net total of €169k worth in shares. Is New 90 Day High Low • Oct 30
New 90-day low: €0.34 The company is down 2.0% from its price of €0.35 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 14% over the same period.